Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada
- PMID: 18444843
- DOI: 10.1086/533469
Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada
Abstract
To assess the risk of Guillain-Barré syndrome (GBS) following administration of meningococcal serogroup C-CRM(197) conjugate vaccine, provincial immunization records were linked with hospital discharge records, and medical charts were reviewed. In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
